Consumer Defensive -
Agricultural Farm Products - NASDAQ - US
$ 25.95
0 %
$ 338 M
Market Cap
None
P/E
1. INTRINSIC VALUE
Balance Sheet
CHS Inc.
| Current Assets | 8.71 B |
| Cash & Short-Term Investments | 1.37 B |
| Receivables | 3.55 B |
| Other Current Assets | 3.78 B |
| Non-Current Assets | 10 B |
| Long-Term Investments | 3.88 B |
| PP&E | 5.4 B |
| Other Non-Current Assets | 732 M |
| Current Liabilities | 5.4 B |
| Accounts Payable | 2.7 B |
| Short-Term Debt | 644 M |
| Other Current Liabilities | 2.06 B |
| Non-Current Liabilities | 2.55 B |
| Long-Term Debt | 1.82 B |
| Other Non-Current Liabilities | 728 M |
EFFICIENCY
Earnings Waterfall
CHS Inc.
| Revenue | 39.3 B |
| Cost Of Revenue | 37.5 B |
| Gross Profit | 1.75 B |
| Operating Expenses | 1.17 B |
| Operating Income | 584 M |
| Other Expenses | -518 M |
| Net Income | 1.1 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CHS Inc.
| Net Income | 1.1 B |
| Depreciation & Amortization | 482 M |
| Capital Expenditures | -832 M |
| Stock-Based Compensation | 0 |
| Change in Working Capital | -324 M |
| Others | 201 M |
| Free Cash Flow | 441 M |
Wall Street Analysts Price Targets
CHS Inc.
CHSCL has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.469 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
CHS Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
41.2 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.
globenewswire.com
- 1 month ago
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif.
globenewswire.com
- 1 month ago
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois.
globenewswire.com
- 2 months ago
Community Health Systems and Denim Health Announce a Development Partnership Designed to Broadly Scale Conversational AI Across the CHS Patient Access Center
FRANKLIN, Tenn. & AUSTIN, Texas--(BUSINESS WIRE)--Community Health Systems, Inc. (NYSE: CYH) (“CHS”) and Denim Health have announced a development partnership that is aimed at revolutionizing the call center experience for patients through the implementation of conversational AI in the CHS Patient Access Center (“PAC”). The PAC is a centralized call center serving nearly 1,000 CHS-affiliated primary care providers and handling more than 25,000 inbound calls daily. CHS and Denim Health have been.
businesswire.com
- 8 months ago
8. Profile
Summary
CHS Inc. CHSCL
COUNTRY
US
INDUSTRY
Agricultural Farm Products
MARKET CAP
$ 338 M
Dividend Yield
0.00%
Description
CHS Inc., an integrated agricultural company, provides grains, foods, and energy resources to businesses and consumers in North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Energy, Ag, Nitrogen Production, and Foods. It is involved in the operation of petroleum refineries and pipelines; supply, marketing, and distribution of refined fuels, including gasoline, diesel fuel, and other energy products; blending, sale, and distribution of lubricants; and the supply of propane and other natural gas liquids. The company also processes and sells crude oil into refined petroleum products under the Cenex brand name to member cooperatives and other independent retailers through a network of approximately 1,500 sites; and provides transportation services. In addition, it markets grains and oilseeds; and offers seeds, crop nutrients, crop protection products, animal feed, animal health products, refined and renewable fuels, and propane, as well as refined oils, meal, soy flour, and processed sunflower products. Further, the company produces and sells nitrogen-based products, including methanol, UAN and urea, and related products; manufactures, packages, and distributes vegetable oil-based products, such as packaged oils, margarine, mayonnaise, flavored dressings, sauces, and other food products; and offers cooperatives with various loans that meet commercial agriculture needs and loans to individual producers, as well as consulting and commodity risk management services. CHS Inc. was incorporated in 1936 and is headquartered in Inver Grove Heights, Minnesota.
Contact
5500 Cenex Drive, Inver Grove Heights, MN, 55077
https://www.chsinc.com
IPO
Date
Jan. 15, 2015
Employees
10014
Officers
Ms. Hanna Olivia Nelligan
Executive Vice President, Chief Financial Officer & Chief Strategy Officer
Mr. Darin Hunhoff
Executive Vice President of Energy
Mr. John C. Lenzi
Vice President of Corporate Compliance
Mr. Thomas R. Medd
Vice President of Marketing & Risk Management
Mr. John A. Griffith
Executive Vice President of Ag Business & CHS Hedging
Mr. Jay D. Debertin
President & Chief Executive Officer
Mr. David Black
Executive Vice President of Enterprise Transformation & Chief Information Officer
Mr. Brandon B. Smith J.D.
Executive Vice President & General Counsel
Mr. Russell A. Kehl
Secretary, Treasurer & Independent Director
Mr. Daniel John Lehmann
Vice President of Finance, Corporate Controller & Chief Accounting Officer